SCHEMBL254200

SCHEMBL254200

C=CCNc1c(O)cc2c(O)c1C[C@@H](C)[C@H](OC)C(O)[C@@H](C)/C=C(\C)C(OC(N)=O)C(OC)/C=C\C=C(/C)C(=O)N2

nearest known ligand 0.81

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 16/20 0.81
HSP90AB1 P08238 9/20 0.81
PDGFRA P16234 1/20 0.81
ERBB2 P04626 2/20 0.47
ALDH1A1 P00352 1/20 0.45
ESR1 P03372 1/20 0.42
RAF1 P04049 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL138856 0.95 HSP90AA1 (0.73) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
SCHEMBL13221597 0.92 HSP90AA1 (0.88) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
SCHEMBL12656246 0.90 HSP90AA1 (0.83) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
SCHEMBL12655972 0.90 HSP90AA1 (0.83) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL13204564 0.90 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL13199500 0.90 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL254489 0.90 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL22496014 0.90 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL14748340 0.90 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1
Retaspimycin SCHEMBL12446217 0.90 HSP90AA1 (0.99) HSP90AA1HSP90AB1PDGFRAERBB2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058982-A1 Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof INFINITY PHARMACEUTICALS, INC. (US) 2012-03-08 US disclosed
US-7767663-B2 Analogs of benzoquinone-containing ansamycins and methods of use thereof INFINITY PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-20090209549-A1 Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof ADAMS JULIAN 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058982-A1 Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof HSP90B1, CDC37, NPM1 HSP90AA1 14/4885HSP90AB1 10/4885PDGFRA 2633/4885
US-20090209549-A1 Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof HSP90B1, CDC37, NPM1 HSP90AA1 14/4885HSP90AB1 10/4885PDGFRA 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.